[Form 4] Vicarious Surgical Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vicarious Surgical Inc. (RBOT) – Form 4 insider transaction

The filing discloses that Adam David Sachs, the company’s Chief Executive Officer, Director and >10% shareholder, executed a single sale of Class A common stock on 06/23/2025. A total of 279 shares were sold at a weighted-average price of $7.7996 per share. The transaction was carried out specifically to satisfy tax-withholding obligations arising from the vesting of restricted stock units granted on 11/23/2021.

Following the disposition, Sachs’ direct beneficial ownership stands at 50,444 Class A shares. No derivative security activity was reported in Table II. The filing states that the price represents an average of multiple trades executed between $7.62 and $7.90; full trade-level detail is available to the SEC or shareholders upon request.

Key contextual points for investors:

• The sale represents less than 1% of Sachs’ reported holdings, indicating a de-minimis impact on his ownership stake.
• The transaction is classified under code “S” (open-market sale) but is explicitly tied to tax withholding and therefore does not necessarily signal a change in sentiment.
• No other transactions, option exercises, or new awards were reported in the filing period.

Overall, the Form 4 reflects a routine administrative sale rather than a strategic reduction, and it is unlikely to materially affect the company’s governance or shareholder structure.

Positive

• None.

Negative

• CEO insider sale, albeit small, may be perceived negatively by some investors even though it is tax-related

Insights

Financial Analyst

TL;DR: Small CEO sale (279 shares) for tax purposes; minimal ownership change, neutral signal.

The 279-share sale equals roughly $2.2 k in proceeds and reduces Sachs’ stake to 50,444 shares, an immaterial adjustment relative to his existing position and RBOT’s 126 million share float. Because the disposition addresses tax withholding linked to RSU vesting, it lacks the informational value typically associated with discretionary insider selling. I view the filing as non-impactful to valuation or liquidity. Investors should monitor cumulative insider activity but treat this isolated event as routine.

Corporate Governance Specialist

TL;DR: Governance perspective—administrative sale, no concern over alignment.

The Form 4 notes Sachs remains a 10% owner, director and CEO even after the sale, keeping strong alignment with minority shareholders. The transaction follows Rule 10b5-1 safeguards, limiting governance risk. No red flags regarding intent or undisclosed derivatives emerge. Therefore, the disclosure is neutral for governance assessments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sachs Adam David

(Last) (First) (Middle)

C/O VICARIOUS SURGICAL INC.

78 FOURTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vicarious Surgical Inc. [ RBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/23/2025		S(1)		279	D	$7.7996(2)	50,444	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units that were granted on November 23, 2021.

2. This figure is the weighted average sales price of multiple trades ranging from $7.62 to $7.90 per share. The Reporting Person undertakes to provide the staff of the Securities Exchange Commission, Vicarious Surgical Inc. or any security holder of Vicarious Surgical Inc.with full information about the number of shares sold at each separate price upon request.

	/s/ Erin Checka, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Vicarious Surgical (RBOT) shares did CEO Adam Sachs sell?

He sold 279 Class A common shares on 06/23/2025.

What was the average sale price of the RBOT shares?

The weighted-average price was $7.7996 per share, with trades between $7.62 and $7.90.

Why did the CEO sell RBOT shares according to the Form 4?

The sale was executed solely to cover tax-withholding obligations tied to vested RSUs.

How many RBOT shares does the CEO own after the transaction?

Adam Sachs now directly owns 50,444 Class A shares.

Does the filing indicate any new options or derivative securities for the CEO?

No. Table II shows no derivative security transactions or new awards.